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Process for the preparation of (11α,13E,15S)-11,15-dihydroxy-9-oxoprost-13-en-
1-oic acid 
 
Field of the invention:  






Background of the invention: 
 (11α,13E,15S)-11,15-dihydroxy-9-oxoprost-13-en-1-oic acid is generally 
known as Prostaglandin E1 (PGE1) or Alprostadil. Alprostadil was approved in US 
and Europe under the brand name of CAVERJECT® and indicated for the treatment 
of erectile dysfunction due to neurogenic, vasculogenic, psychogenic, or mixed 15 
etiology.  
 Biosynthetic PGE1, is formed from dihomo-γ-linolenic acid was disclosed in 
Prostaglandin 20, 187, 1980. Syntheses of PGE1 was disclosed in J. Chem. Soc. 
Chem. Comm 304, 1972; J. Chem. Soc. Chem. Comm. 180, 1973; J Am. Chem. Soc. 
94, 3643, 1972; J. Am. Chem Soc. 95, 1676, 1973; J. Org. Chem. 37, 2921, 1972. 20 
Another possible approach is the regioselective saturation of the cis double bonds of 
the prostanoid structure containing cis and trans double bonds. Hydrogenation of 
5(Z), 11α, 13E, 15(S)-11,15-dihydroxy-9-oxoprosta-5,13-diene-1-oic-acid (PGE2) of 
formula in ethyl acetate yields only 6% of PGE1 (J Biol. Chem 239, 4091 1964). 
  25 
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 Journal of Medicinal Chemistry, 29(10), 1826-32, 1986 discloses the 
preparation of protected Alprostadil analogous compound. US4024174A; American 
Chemical Society, 92(8), 2586-7, 1970; WO1997022581A1 discloses reduction of 
double bond at C5-C6 position in Prostaglandin acid compound.  
 5 
 The present inventors developed a process for the preparation of 
compound of (11α,13E,15S)-11,15-dihydroxy-9-oxoprost-13-en-1-oic acid with 
higher yield and purity by reducing the impurities. 
 
Brief description of the invention: 10 
The present invention provides a process for the preparation of Alprostadil of 
formula-1.  
 
Detailed description of the Invention: 
 As used herein the term “suitable solvent” or “solvent” used in the present 15 
invention refers to “hydrocarbon solvents” such as n-hexane, n-heptane, cyclohexane, 
pet ether, benzene, toluene, pentane, cycloheptane, methyl cyclohexane, 
ethylbenzene, m-, o-, or p-xylene, or naphthalene and the like; “ether solvents” such 
as dimethoxymethane, tetrahydrofuran, 1,3-dioxane, 1,4-dioxane, furan, diethyl ether, 
ethylene glycol dimethyl ether, ethylene glycol diethyl ether, diethylene glycol 20 
dimethyl ether, diethylene glycol diethyl ether, triethylene glycol dimethyl ether, 
anisole, t-butyl methyl ether,  1,2-dimethoxy ethane and the like; “ester solvents” 
such as methyl acetate, ethyl acetate, isopropyl acetate, n-butyl acetate and the like; 
“polar-aprotic solvents such as dimethylacetamide (DMA), dimethylformamide 
(DMF), dimethylsulfoxide (DMSO), N-methylpyrrolidone (NMP) and the like; 25 
“chloro solvents” such as dichloromethane, dichloroethane, chloroform, carbon 
tetrachloride and the like; “ketone solvents” such as acetone, methyl ethyl ketone, 
methyl isobutylketone and the like; “nitrile solvents” such as acetonitrile, 
propionitrile, isobutyronitrile and the like; “alcohol solvents” such as methanol, 
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ethanol, n-propanol, isopropanol, n-butanol, isobutanol, t-butanol, 2-nitroethanol, 2-
fluoroethanol, 2,2,2-trifluoroethanol, ethylene glycol, 1,2-propanediol (propylene 
glycol), 2-methoxyethanol, l, 2-ethoxyethanol, diethylene glycol, 1, 2, or 3-pentanol, 
neo-pentyl alcohol, t-pentyl alcohol, diethylene glycol monoethyl ether, 
cyclohexanol, benzyl alcohol, phenol, or glycerol and the like; water or mixtures or 5 
any other suitable solvent known in the art. 
 The term “suitable base” used in the present invention refers to inorganic 
bases selected from “alkali metal carbonates” such as sodium carbonate, potassium 
carbonate, lithium carbonate, cesium carbonate and the like; “alkali metal 
bicarbonates” such as sodium bicarbonate, potassium bicarbonate, lithium 10 
bicarbonate, cesium bicarbonate and the like; “alkali metal hydroxides” such as 
sodium hydroxide, potassium hydroxide, lithium hydroxide and the like; “alkyl 
metals” such as n-butyl lithium and like; “metal hydrides” such as sodium hydride, 
potassium hydride, lithium hydride and the like; “alkali metal phosphates” such as 
disodium hydrogen phosphate, dipotassiumhydrogen phosphate; and “organic bases” 15 
selected from but not limited to methyl amine, ethyl amine, dimethylamine, 
diethylamine, diisopropylamine, diisopropylethyl amine (DIPEA), diisobutylamine, 
triethylamine, tert.butylamine, pyridine, 4-dimethylaminopyridine (DMAP), N-
methyl morpholine (NMM), 2,6-lutidine, lithium diisopropylamide, nmethyl pyridine 
(NMP), 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU), 1,5-diazabicyclo[4.3.0] non-5-20 
ene (DBN), 1,4-diazabicyclo[2.2.2]octane (DABCO), imidazole; “organo lithium 
bases” such as methyl lithium, n-butyl lithium, tert-Butyllithium,   phenyl lithium and 
the like; “alkali metal alkoxides” such as sodium methoxide, sodium ethoxide, 
potassium methoxide, potassium ethoxide, sodium tert.butoxide, potassium 
tert.butoxide, lithium tert.butoxide and the like; “alkali metal amides” such as sodium 25 
amide, potassium amide, lithium amide, lithium diisopropyl amide (LDA) and the 
like; ammonia such as aqueous ammonia, ammonia gas, alcoholic ammonia; 
organosilicon bases such as sodium bis(trimethylsilyl)amide (NaHMDS), potassium 
bis(trimethylsilyl)amide, lithium bis(trimethysilyl)amide (LiHMDS), potassium 
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hexamethyldisilazide (KHMDS) and the like; or mixtures or any other suitable base 
known in the art. 
 As used herein term, "an alcohol protecting group" is a functional group that 
protects the alcohol group from participating in reactions that are occurring in other 
parts of the molecule. Suitable alcohol protecting groups that are used in step (a) 5 
include, acetyl, benzoyl, benzyl, β-methoxyethoxymethyl ether, methoxymethyl ether, 
dimethoxytrityl, p-methoxybenzyl ether, methylthiomethyl ether, allyl ether, t-butyl 
ether, pivaloyl, trityl, silyl ether (e.g., trimethylsilyl (TMS), t-butyldimethylsilyl 
(TBDMS), t-. butyldiphenylsilyl (TBDPS), t-butyldimethylsilyloxymethyl (TOM) or 
triisopropylsilyl (TIPS) ether), tetrahydropyranyl (THP), methyl ether and 10 





Wherein R is selected from straight or branched C1-C10 “alkyl” or optionally 




 are H or “an alcohol 









 The first embodiment of present invention provides a process for the 
preparation of Alprostadil of formula-1 comprising; 
a) converting compound of formula-13 to compound of formula-14, 
b) ester hydrolysis of compound of formula-14 with a base in a solvent to provide 
compound of formula-15, 5 
c) converting compound of formula-15 to Alprostadil of formula-1. 
  
 Converting compound of formula-13 to compound of formula-14 in step-a) of 
the second embodiment can be done by reduction of double bond at C5-C6 position of 
the compound of formula-13 with hydrogenating agent in a solvent optionally in 10 
presence of a base to provide compound of formula-14. 
Wherein the hydrogenating agent is selected from Pd/C, Pd(OH)2/C 
(Pearlman's catalyst), palladium acetate, platinum oxide, platinum black, sodium 
borohydride, Na-liquid ammonia, Raney-Ni, tri(C1-C6)alkylsilanes, tri(C1-
C6)alkylsilyl halides and the like optionally in presence of hydrogen gas;  the solvent 15 
is selected from alcohol solvents, ester solvents, chloro solvents, ether solvents, 
hydrocarbon solvents, polar aprotic solvents, polar solvents such as water and/or 
mixtures thereof; the base is selected from organic or inorganic bases. 
 
 The second embodiment of present invention provides a process for the 20 
preparation of Alprostadil of formula-1 comprising; 
a) converting compound of formula-13 to compound of formula-14, 
b) ester hydrolysis of compound of formula-14 with a base in a solvent to provide 
compound of formula-15, 
c) oxidation of the compound of formula-15 with an oxidizing agent in a solvent to 25 
provide the compound of formula-16, 
d) deprotecting the hydroxyl protecting group of formula-16 in a solvent to provide 
Alprostadil of formula-1. 
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Converting compound of formula-13 to compound of formula-14 in step-a) of 
the second embodiment can be done by reduction of double bond at C5-C6 position 
of the compound of formula-13 with hydrogenating agent in a solvent optionally in 
presence of a base to provide compound of formula-14, wherein the hydrogenating 
agent is selected from Pd/C, Pd(OH)2/C (Pearlman's catalyst), palladium acetate, 5 
platinum oxide, platinum black, sodium borohydride, Na-liquid ammonia, Raney-Ni, 
tri(C1-C6)alkylsilanes, tri(C1-C6)alkylsilyl halides and the like optionally in 
presence of hydrogen gas; oxidizing agent in step-c) is selected from but is not 
limited to nitric acid, hydrogen peroxide, per acids such as peracetic acid, trifluoro 
per acetic acid, per benzoic acid, m-chloroperbenzoic acid and the like, ozone, 10 
manganese dioxide, sodium periodate, dinitrogen tetroxide, hydroperoxide, 
iodobenzene acetate, t-butyl hypochlorite, sulfuryl chloride, potassium 
peroxymonosulfate, potassium permanganate, chromic acid, chromium trioxide, 
selenium dioxide, sodium hypochlorite, sodium metaperiodate, ruthenium trichloride, 
TEMPO, DABCO, Dess-martin reagent, oxaloyl chloride in DMSO and the like or 15 
any other suitable oxidizing agent known in the art.; deprotecting agent in step-d) is 
selected from but not limited to acids such as hydrochloric acid, hydrobromic acid, 
sulfuric acid, nitric acid, aq.phosphoric acid, trifluoroacetic acid, methane sulfonic 
acid, p-toluenesulfonic acid, acetic acid and the like; acetyl chloride in combination 
with alcohols; bases such as alkali metal hydroxides, alkali metal alkoxides, alkali 20 
metal carbonates, cesium carbonate/imidazole, ammonia, cerium(IV) ammonium 
nitrate (CAN); organic bases such as methylamine, ethylamine, diethylamine, 
triethylamine, piperidine and the like or any other suitable deprotecting agent known 
in the art; the solvent is selected from alcohol solvents, ester solvents, chloro 
solvents, ether solvents, hydrocarbon solvents, polar aprotic solvents, polar solvents 25 









Compound of formula-13 used in the present invention can be prepared by 
any of the processes disclosed in literature such as US 6359181B1 or other references 
such as Journal of the Chemical Society Chemical communications, 1975, 658; J. 
Am. Chem. Soc. 1974, 96, 18, 5876–5894; J. Org. Chem. 1979, 44, 13, 2194–2199 or 
as per the present application. 5 
 
The third embodiment of the present invention schematically provides the 
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The fourth embodiment of the present invention provides substantially pure 
Alprostadil of formula-1 and its intermediates. The term “substantially pure” refers to 
the compound obtained according to the present invention having purity of greater 
than about 95%; preferably greater than about 97.5%; more preferably greater than 
about 99.0% as measure by HPLC.  5 
Alprostadil of formula-1 prepared according to the present invention can be 
further micronized or milled to get desired particle size to achieve desired solubility 
profile based on different forms of pharmaceutical composition requirements. 
Techniques that may be used for particle size reduction include but not limited to 
single or multi-stage micronization using cutting mills, pin/cage mills, hammer mills, 10 
jet mills, fluidized bed jet mills, ball mills and roller mills. Milling or micronization 
may be performed before drying or after drying of the product. 
The fifth embodiment of the present invention provides a pharmaceutical 
composition comprising the crystalline form of Alprostadil of formula-1 and at least 
one pharmaceutically acceptable excipient. As used herein, the term "pharmaceutical 15 
compositions" or "pharmaceutical formulations" include tablets, pills, powders, 


















The best mode of carrying out the present invention was illustrated by the 
below mentioned examples. These examples are provided as illustration only and 
hence should not be construed as limitation of the scope of the invention. 
 
Examples: 5 
Example-1: Preparation of dimethyl-(2-oxoheptyl)phosphonate (Formula-3) 
n-Butyl lithium (119 ml) was slowly added to a pre-cooled mixture of dimethyl 
phosphonate (22.07 ml) and tetrahydrofuran (140 ml) at -65 to -70°C and stirred the 
resultant solution at the same temperature. A solution of ethyl hexanoate (14 g) in 
tetrahydrofuran was added to the above reaction mixture at the same temperature and 10 
stirred. The reaction mixture was quenched with aqueous ammonium chloride 
solution and extracted with ethyl acetate. Combined the organic layers and washed 
with water and distilled off the solvent from the organic layer to get the title 
compound. 
Yield: 20 g. 15 
 
Example-2: Preparation of Formula-7a 
A mixture of imidazole (29.65 g) and tert-butyldimethylsilyl chloride [TBDMSiCl] 
(48.07 g) were added to pre-cooled solution of Corey lactone compound of formula-4 
(50 g) in dichloromethane (750 ml) at 0-5°C and stirred the resultant mixture at the 20 
same temperature. Water was added to the above reaction mixture. The organic layer 
was washed with water and followed by aqueous sodium chloride solution. Distilled 
off solvent completely from the organic layer under reduced pressure. 
Dichloromethane (500 ml) is added to obtained residue at 25-30°C and cooled to 0-
5°C. Camphor sulphonic acid (1.68 g), 3,4-dihydropyran (34.35 g) are added to the 25 
resultant mixture and followed by added 10% of aqueous sodium bicarbonate 
solution at the same temperature. Raised the temperature of the reaction mixture to 
25-30°C and stirred. Both the aqueous and organic layers were separated. The 
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aqueous layer was extracted with dichloromethane. Combined the organic layers and 
washed with aqueous sodium bicarbonate solution and followed by aqueous sodium 
chloride solution. Distilled off solvent completely from the organic layer under 
reduced pressure. Tetrahydrofuran (600 ml) was added to the above obtained residue 
at 25-30°C. Cooled the mixture to 0-5°C and a solution of tetrabutyl ammonium 5 
fluoride (106.28 g) in tetrahydrofuran (600 ml) was slowly added to the above 
mixture and stirred. Water and dichloromethane were added to the above reaction 
mixture. The aqueous layer was extracted with dichloromethane and combined the 
organic layers. The organic layer was washed with aqueous sodium chloride solution. 
Distilled off solvent completely from the organic layer to get the title compound. 10 
Yield: 49.3 g 
 
Example-3: Preparation of Formula-9a 
Oxalyl chloride (41.44 g) was slowly added to pre-cooled mixture of 
dichloromethane (400 ml) and dimethyl sulfoxide (37.80 g) at -70°C and stirred at the 15 
same temperature. The solution of compound of formula-7a (40 g) in 
dichloromethane was added to the above mixture at the same temperature and stirred. 
Raised the temperature of the reaction mixture to -40°C to -45°C and stirred at the 
same temperature. Cooled the mixture to -70°C to -75°C. Triethylamine (89.85 g) 
was added the above mixture at the same temperature and stirred. Water was added to 20 
the above mixture at 25-30°C. The aqueous layer was extracted with 
dichloromethane. Combined the organic layers and washed with water. Distilled off 
solvent completely from the organic layer under reduced pressure. The obtained 
residue was dissolved in tetrahydrofuran and kept a side. Dimethyl-(2-
oxoheptyl)phosphonate of formula-3 (34.69 g) and zinc chloride (27.99 g) was added 25 
to the mixture of tetrahydrofuran (400 ml) and sodium hydroxide (9.36 g) mixture at 
25-30°C and stirred. The above obtained solution was added to this reaction mixture 
at 25-30°C and stirred at the same temperature. 10% sodium chloride solution was 
added to the reaction mixture at 25-30°C. The aqueous layer was extracted with ethyl 
11




acetate. Combined the organic layers and washed with water.  Distilled off solvent 
completely from the organic layer and the obtained compound was purified by 
column chromatography using petroleum ether and ethyl acetate as eluents. Distilled 
off solvent from the pure fractions to get pure title compound.  
Yield: 20.0 g 5 
 
Example-4: Preparation of Formula-10a 
(R)-2-Methyl-CBS-oxazaborolidine catalyst (13.84 g) was slowly added to the 
mixture of compound of formula-9a (35 g) and tetrahydrofuran (350 ml) at 25-30°C 
and stirred at the same temperature. Cooled the mixture to -25°C to -30°C and 10 
borane-dimethyl sulfide (5.68 g) was slowly added to the above mixture at the same 
temperature and stirred. Quenched the reaction mixture with methanol. Aqueous 
ammonium chloride solution and ethyl acetate were added to the above mixture. The 
aqueous layer was extracted with ethyl acetate and combined the organic layers. The 
organic layer was washed with aqueous citric acid solution and followed by water. 15 
Distilled off solvent completely from the organic layer. The obtained compound is 
purified by silica column chromatography with cyclohexane and ethyl acetate as 
eluents and distilled the pure fractions to get the pure title compound. 
Yield: 27.0 g 
 20 
Example-5: Preparation of Formula-11a 
Para toluenesulfonic acid (6.595 g) was added to the pre-cooled mixture of 
dichloromethane (270 ml) and sodium sulphate (5 g) and compound of formula-10a 
(27 g) at 0-5°C. 3,4-Dihydropyran (32.21 g) was added to the above reaction mixture 
at the same temperature and stirred at the same temperature. Water was added to the 25 
mixture. The aqueous layer was extracted with dichloromethane and combined the 
organic layers. The organic layer was washed with aqueous sodium bicarbonate 
solution and followed by water and aqueous sodium chloride solution. Distilled off 
the solvent completely from the organic layer. The obtained compound was purified 
12
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by silica column chromatography using cyclohexane and ethyl acetate as eluents and 
distilled off the solvent from pure fractions to get pure title compound. 
Yield: 27.0 g 
 
Example-6: Preparation of Formula-13a 5 
25% of Diisobutylaluminium hydride (30.78 ml) was added to pre-cooled mixture of 
compound of formula-11a (27.0 g) and tetrahydrofuran (270 ml) at -70°C to -75°C 
and stirred. Quenched the above reaction mixture with methanol at the same 
temperature. Ethyl acetate and water was added to the above mixture. Raised the 
temperature of the mixture to 25-30°C and stirred. The aqueous layer was extracted 10 
with ethyl acetate and combined the organic layers. Distilled off solvent completely 
from the organic layer. 54 ml of tetrahydrofuran is added to the obtained compound at 
25°C-30°C. The solution was added to pre-cooled mixture of tetrahydrofuran (270 
ml), (4-carboxybutyl)triphenylphosphonium bromide [Wittig salt] (82.23 g) and 
potassium tert-butoxide (41.63 g) at 0°C-5°C. Stirred the reaction mixture at 0-5°C. 15 
10% citric acid solution followed by ethyl acetate were added to the above mixture. 
The aqueous layer was extracted with ethyl acetate and combined the organic layers. 
The organic layer was washed with water and followed by aqueous sodium chloride 
solution. Distilled off solvent completely from the organic layer under reduced 
pressure. The obtained compound was added to acetone (270 ml) at 25-30°C and 20 
cooled the above mixture to 0-5°C. Potassium carbonate (25.64 g) and methyl iodide 
(52.67 g) were added to above mixture at the same temperature and raised the 
temperature of the reaction mixture to 25-30°C and stirred. Dichloromethane and 
water were added the mixture. The aqueous layer was extracted with dichloromethane 
and combined the organic layers. The organic layer was washed with water. Distilled 25 
off solvent completely from the organic layer. The obtained compound was purified 
by silica column chromatography using cyclohexane and ethyl acetate as eluents. 
Distilled off the solvent from pure fractions and get pure title compound. 
Yield: 16.6 g 
13




Example-7: Preparation of Formula-14a 
Palladium carbon (3.56 g) was added to the mixture of triethylamine (0.8 ml), 
compound of formula-13a (16.0 g) and dichloromethane (80.0 ml) at 25-30°C. 
Applied 4-5 kg hydrogen pressure to the reaction mixture and stirred. The mixture 
was filtered through hyflow bed and washed with dichloromethane. Dichloromethane 5 
& water were added to the obtained filtrate. Both the aqueous and organic layers were 
separated. The organic layer was washed with water. Distilled off solvent completely 
from the organic layer and dried to get the compound of formula-14a. 
Yield: 15.8 g 
Example-8: Preparation of Formula-15a 10 
Aqueous sodium hydroxide solution was added to pre-cooled solution of compound 
of formula-14a (15.8 g) in methanol (158 ml) at 0-5°C and stirred it at the same 
temperature. Water and methyl tert-butyl ether were added to the above mixture. Both 
the aqueous and organic layers were separated. Aqueous citric acid solution was 
added to the aqueous layer and extracted with methyl tert-butyl ether. The organic 15 
layer was washed with water and followed by aqueous sodium chloride solution. 
Distilled off solvent completely from the organic layer and dried to get the compound 
of formula-15a. 
Yield: 14.0 g 
Example-9: Preparation of Formula-16a 20 
Dess-martin periodinane (16.98 g) was added to the pre-cooled solution of compound 
of formula-15a (14 g) in dichloromethane (140 ml) at 0-5°C. Raised the temperature 
of the reaction mixture to 25-30°C and stirred. Water was added to the obtained 
mixture. Both the aqueous and organic layers were separated. The organic layer was 
washed with aqueous sodium bicarbonate solution and followed by water. Distilled 25 
off solvent completely from the organic layer. The obtained compound was purified 
by silica gel column chromatography using cyclohexane and ethyl acetate as eluents 
to get the compound of formula-16a.  
Yield: 11.6 g. 
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Example-10: Preparation of Alprostadil  
Acetic acid (114 ml) was slowly added the pre-cooled mixture of compound of 
formula-16a (6 g), tetrhydrofuran (18 ml) and water (60 ml) at 0-5°C. Heated the 
reaction mixture to 45-50°C and stirred. Distilled off the solvent completely from the 
resultant mixture. Aqueous sodium carbonate solution followed by ethyl acetate were 5 
added to the resultant mixture at 25-30°C. Both the aqueous and organic layers were 
separated. The organic layer was washed with water. Distilled off solvent completely 
from the organic layer. The obtained compound was recrystallized from ethyl acetate 
and dried to get the title compound. 
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